Meloxicam for Dogs: Dose, Uses, and Warnings

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-09-20

Meloxicam for dogs is a prescription nonsteroidal anti-inflammatory drug (NSAID) that reduces pain, inflammation, and fever. It is classified as a preferential COX-2 inhibitor, meaning it blocks the enzyme that drives inflammation more than the enzyme that protects the stomach and kidney [1]. In canine medicine it is used most often for osteoarthritis, for postoperative pain after orthopedic and soft tissue surgery, and as an adjunct in some cancer protocols [2][3][4][5]. It is available as an oral suspension, oral tablets, an oral transmucosal spray, and an injectable solution, and every one of those forms requires a veterinarian's prescription.

Meloxicam is not a painkiller you can dose by guesswork. The label uses a higher initial dose followed by a lower maintenance dose, and the gap between a therapeutic dose and a toxic one is narrower in dogs than many owners assume. This article covers how meloxicam works, what it is labeled to treat, how it is given, which dogs should never receive it, and the monitoring that keeps a canine NSAID patient safe.

This article is educational and is not a substitute for veterinary diagnosis or treatment.

At a Glance

What Meloxicam Is and How It Works

The COX-1 and COX-2 story

Every NSAID works by inhibiting cyclooxygenase, or COX, the enzyme that converts arachidonic acid into prostaglandins. Two isoforms of COX matter here. COX-1 is present at a fairly constant level in most tissues and produces prostaglandins that protect the stomach lining and support normal kidney blood flow. COX-2 is induced by inflammation and produces the prostaglandins that drive pain, swelling, and fever [1].

The therapeutic benefit of an NSAID comes from blocking COX-2. The classic side effects, particularly stomach irritation and kidney injury, come from blocking COX-1 [1]. Drugs differ in how selectively they hit one isoform over the other. Meloxicam has been shown in multiple test systems to be a preferential inhibitor of COX-2, which is why it sits in a middle category between older nonselective NSAIDs and the highly COX-2 selective coxibs [1].

"Preferential" is not the same as "selective." Meloxicam still inhibits COX-1 to some degree, and that residual COX-1 activity is exactly why the contraindication list and the monitoring plan matter. A dog with a marginal stomach lining, a borderline kidney, or a dehydrated body has less reserve to absorb even a modest COX-1 hit.

What happens after a dose

Meloxicam is completely absorbed from the gastrointestinal tract and has an elimination half-life of about 24 hours in the dog [1]. That long half-life is the pharmacological reason the drug is dosed once daily rather than two or three times a day.

Absorption is not instant. In a pharmacokinetic comparison of meloxicam and ketoprofen in healthy dogs, meloxicam given orally at 0.2 mg/kg reached its peak plasma concentration at roughly 8.5 hours, with a terminal half-life of about 12 hours in that study population [6]. Other work in beagles found mean elimination half-lives in the range of roughly 29 to 33 hours depending on formulation [7]. The practical takeaway is consistent across studies: meloxicam builds up slowly and clears slowly, so the drug accumulates if you dose more often than the label says.

Meloxicam is metabolized to biologically inactive metabolites that are excreted in urine and feces. Those metabolites do not inhibit prostaglandin synthesis in the kidney, which is one reason the parent drug's COX-1 activity, not its breakdown products, is the safety concern [1].

Labeled Uses of Meloxicam in Dogs

Osteoarthritis pain and inflammation

Osteoarthritis is the flagship indication. In a clinical trial of 40 dogs with chronic osteoarthritis, meloxicam produced significant reductions in lameness, general stiffness, painful rising, exercise intolerance, and behavior changes after four weeks of therapy, with side effects that were minimal in extent and duration [3]. A separate multicenter trial of 280 client-owned dogs found that 72.6 percent of dogs on a transmucosal oral meloxicam spray were treatment successes at 28 days, compared with 46.9 percent of placebo-treated dogs, based on client-specific outcome measures. Gastrointestinal effects were observed in some animals in that trial [8].

A more recent randomized trial compared daily oral meloxicam with monthly bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in 101 dogs with appendicular osteoarthritis. Both groups improved significantly from baseline, and while the bedinvetmab group had a larger mean reduction in Canine Orthopaedic Index scores, the difference between groups was not statistically significant [2]. That result is worth understanding: it does not mean meloxicam is ineffective. It means that in that trial, a well-established NSAID performed comparably to a newer biologic on the primary efficacy endpoint.

Perioperative and postoperative pain

Meloxicam is widely used around surgery. In dogs undergoing stifle joint surgery for cranial cruciate ligament rupture, preoperative meloxicam plus butorphanol produced lower adjusted pain scores at several postoperative time points and a lower total serum cortisol response than butorphanol alone [5]. A separate study of dogs undergoing ovariohysterectomy examined the plasma disposition of meloxicam given intravenously at 0.2 mg/kg and found that surgery altered the drug's distribution, with a smaller volume of distribution and higher drug exposure in the surgical group [9]. That finding supports using meloxicam as part of a planned perioperative protocol rather than improvising doses on the day of surgery.

Cancer-associated inflammation

Cyclooxygenase inhibitors have demonstrated antitumor activity in canine urothelial cell carcinoma, both alone and with chemotherapy. In a retrospective multi-institutional study of 28 dogs with non-resectable urothelial cell carcinoma, meloxicam combined with mitoxantrone or vinblastine as first-line treatment produced partial responses or stable disease in most dogs, with a median time to tumor progression of 84 days. Gastrointestinal adverse effects occurred in 21.4 percent of patients, most commonly grade 1 to 2 diarrhea [4]. This is an off-label oncology use directed by a veterinary oncologist, not a home treatment.

What meloxicam does not do

Meloxicam does not reverse joint damage, cure osteoarthritis, or replace weight management, physical rehabilitation, or joint support. It controls the pain and inflammation component. It is not an antibiotic, not a steroid, and not a substitute for addressing the underlying cause of lameness. A dog that limps because of a torn cruciate ligament, an infected joint, or a bone tumor needs a diagnosis, not just an NSAID.

How Meloxicam Is Given

The initial dose then maintenance pattern

Canine meloxicam labels follow a two-step pattern: a higher initial dose to reach therapeutic plasma levels quickly, followed by a lower once-daily maintenance dose. This is the standard structure for the oral suspension and the injectable product. Because the exact numbers differ by product, formulation, and country of approval, the only dose you should use is the one printed on your dog's specific label and confirmed by your veterinarian.

Do not convert a dose from one formulation to another. An oral suspension, a chewable tablet, a transmucosal spray, and an injectable solution are not interchangeable milligram for milligram without veterinary direction, and the concentration on the bottle is what determines the volume you draw.

Giving oral meloxicam

Give oral meloxicam with food. The feline long-term safety study specifically describes administration with food as part of the safe-use protocol, and the same principle applies to dogs: food reduces the direct contact of the drug with the stomach lining and slows absorption slightly, which is generally desirable [10].

Use the dosing syringe or measuring device that comes with the product. Kitchen spoons are not accurate. Shake liquid suspensions as directed on the label. If your dog spits out a dose or you are unsure how much was swallowed, do not give a second full dose to compensate. Call your veterinarian.

The transmucosal spray

The transmucosal oral spray is applied to the oral mucosa rather than swallowed as a liquid. In the 280-dog trial, the spray was given once daily for 28 days and was found safe and effective for osteoarthritis pain and inflammation [8]. Follow the specific application instructions on that product's label, because the technique differs from oral suspension dosing.

Injectable meloxicam

Injectable meloxicam is a clinic product. It is given subcutaneously or intravenously by a veterinarian, typically as a single perioperative dose or as the loading step before transitioning to oral maintenance [5]. The 0.2 mg/kg intravenous dose used in the stifle surgery study and the ovariohysterectomy disposition study reflects clinical practice in those settings, and it is a veterinary decision, not an owner decision [9][5].

Decision Path for Starting Meloxicam

The flowchart below shows the sequence a veterinarian works through before and during meloxicam therapy.

flowchart TD
    A[Dog has pain or inflammation] --> B[Confirm diagnosis]
    B --> C[Baseline blood and urine tests]
    C --> D{Any contraindication}
    D -->|Yes| E[Choose alternative analgesia]
    D -->|No| F[Start label initial dose]
    F --> G[Reduce to label maintenance dose]
    G --> H[Recheck at planned intervals]
    H --> I{Adverse signs or lab changes}
    I -->|Yes| J[Stop drug and contact vet]
    I -->|No| K[Continue with monitoring]

Side Effects and What to Do About Them

Gastrointestinal signs

The most common NSAID adverse effects in dogs are vomiting, diarrhea, and anorexia. A systematic review of 64 prospective studies on NSAID adverse effects in dogs found that adverse effects were detected in 55 percent of the studies reviewed, and that vomiting, diarrhea, and anorexia were the most frequently reported signs [11]. That statistic describes how often these signs appear across the NSAID literature, not the risk for any single dog on a correct dose.

Meloxicam specifically carries a high strength of evidence rating for safety in that systematic review, alongside carprofen and firocoxib [11]. High strength of evidence means the safety data are relatively robust and applicable, not that the drug is risk-free.

Mild, transient stomach upset can occur. Persistent vomiting, diarrhea that does not resolve, black tarry stools, fresh blood in the stool, or a dog that stops eating needs veterinary attention and usually means stopping the drug. In a documented meloxicam overdose case, a dog that received up to 5.5 mg/kg developed self-limiting hematochezia, which is blood in the stool, along with mild azotemia [12]. Blood in the stool is a red flag, not a wait-and-see sign.

Kidney effects

NSAIDs reduce prostaglandin-mediated blood flow within the kidney. A dog with normal kidney function and normal hydration tolerates this well. A dog that is dehydrated, has pre-existing kidney disease, or is receiving other kidney-stressing drugs does not. The overdose case above presented with mild azotemia, meaning elevated kidney values, and follow-up bloodwork eight weeks later still showed relatively static mild azotemia [12]. Kidney injury from NSAIDs can persist.

Liver effects

Hepatic impairment is a contraindication because the liver handles drug metabolism and because NSAID-associated liver injury is a recognized, if uncommon, event in dogs. Baseline liver values and periodic rechecks are part of safe prescribing.

What to do if you suspect a problem

Stop the medication and call your veterinarian or a pet poison control service. Do not give activated charcoal, do not induce vomiting, and do not wait for the next scheduled dose to "see how it goes." Bring the bottle so the exact concentration and the amount given can be calculated.

Which Dogs Should Not Receive Meloxicam

The contraindication checklist

Do not give meloxicam, and tell your veterinarian if any of the following apply:

1. Gastrointestinal ulceration or a history of GI bleeding. An NSAID that reduces protective prostaglandins can worsen existing ulcers.
2. Renal impairment. Reduced kidney reserve makes NSAID-related kidney injury more likely.
3. Hepatic impairment. Impaired liver function affects drug handling and raises the risk of hepatic adverse effects.
4. Dehydration, shock, or hypotension. These states already compromise kidney perfusion, and adding an NSAID compounds the risk.
5. Concurrent corticosteroid therapy. Combining an NSAID with a steroid increases the risk of gastrointestinal ulceration.
6. Concurrent use of another NSAID. Never stack NSAIDs, including aspirin, carprofen, firocoxib, or human products.
7. Pregnancy, breeding, or nursing. Meloxicam is contraindicated in pregnant dogs. Discuss alternatives with your veterinarian if your dog is pregnant or intended for breeding.
8. Known hypersensitivity to meloxicam or another oxicam.
9. Age or weight below the specific product's label minimum. Do not use a product labeled for adult dogs in a puppy unless the label and your veterinarian say so.

A note on aspirin and human NSAIDs

Owners sometimes assume that because aspirin is available over the counter it is safe to combine with a prescription NSAID. It is not. Aspirin irreversibly inhibits COX, and its effects on platelets and the stomach lining persist for days after the last dose. A dog transitioning from aspirin to meloxicam needs a washout period determined by a veterinarian.

Drug Interactions to Know

The clinically important interactions for meloxicam in dogs fall into a few groups.

Other NSAIDs and corticosteroids. This is the highest-risk combination for gastrointestinal ulceration. Avoid it entirely unless a veterinarian has made a deliberate, monitored decision.

Nephrotoxic drugs. Aminoglycoside antibiotics, amphotericin B, and certain other drugs stress the kidney. Combining them with an NSAID in a dehydrated or compromised dog multiplies the risk.

Drugs that affect fluid balance. Diuretics and ACE inhibitors change kidney perfusion. A dog on these drugs needs careful assessment before starting meloxicam.

Protein-bound drugs. Meloxicam is highly protein bound, so drugs that compete for the same binding sites can shift free drug concentrations. This is a pharmacokinetic consideration your veterinarian will weigh when your dog is on multiple medications.

Anesthetics and analgesics. Meloxicam is commonly combined with opioids such as butorphanol in perioperative protocols, and that combination has been studied in dogs undergoing stifle surgery [5]. This is a planned clinical combination, not a reason to combine drugs at home.

Monitoring: The Safety Plan for NSAID Therapy

Baseline testing

Before starting meloxicam, a veterinarian should have baseline renal and hepatic panels and a packed cell volume (PCV). The renal panel assesses kidney function through values such as blood urea nitrogen and creatinine. The hepatic panel assesses liver enzymes and proteins. The PCV measures the proportion of blood volume made up of red blood cells and helps detect anemia, which can result from chronic gastrointestinal blood loss.

Baseline testing does two things. It identifies dogs that should not receive the drug at all, and it creates a comparison point so that later changes can be attributed to the drug rather than to pre-existing disease.

Ongoing monitoring

Recheck intervals depend on the individual dog, the dose, the duration of therapy, and any concurrent disease. A reasonable structure is:

1. Clinical signs at every refill. Ask specifically about appetite, vomiting, stool consistency, stool color, energy, and water intake.
2. Periodic renal and hepatic panels. Frequency is set by the veterinarian, with shorter intervals for older dogs, dogs on long-term therapy, and dogs with any organ compromise.
3. Periodic PCV. Anemia can develop silently from chronic low-grade gastrointestinal bleeding.
4. Body weight. Dose is weight-based, and a dog that gains or loses significant weight may need a dose adjustment.
5. Owner-observed pain and function. The same client-specific outcome measures used in clinical trials are useful at home: how well does the dog rise, walk, climb stairs, and play [8].

A monitoring table

Species Differences: Dogs, Cats, and Other Animals

Cats are not small dogs

Meloxicam is approved for cats, but the feline regimen is fundamentally different. Cats require a single-dose regimen for many indications and are more sensitive to NSAID adverse effects than dogs. The long-term feline safety study used oral meloxicam at 0.01 to 0.03 mg/kg once daily in 40 cats with osteoarthritis over a mean treatment duration of 5.8 months. Gastrointestinal upset occurred in 2 of 46 cats, and no deleterious effect on renal function was detected in the cats studied [10].

That study describes a carefully selected, monitored population on a specific low dose. It is not permission to give a dog's meloxicam to a cat. The concentrations and dosing devices differ, and a cat given a dog-sized dose can suffer serious harm.

Other species

Meloxicam pharmacokinetics vary widely across species. In prairie dogs, a low subcutaneous dose of 0.2 mg/kg fell below the presumed therapeutic range before 24 hours, while a 4 mg/kg dose stayed above it for more than 72 hours [13]. In California sea lions and Pacific harbor seals given a single oral dose of 0.1 mg/kg, elimination half-lives were approximately 32 hours, longer than previously recommended dosing intervals assumed [14]. In cattle, meloxicam has less inhibitory effect on gastrointestinal smooth muscle motility than flunixin meglumine, which is relevant when choosing an NSAID in ruminants [15].

The lesson for dog owners is simple: meloxicam dosing is species-specific and formulation-specific. Never use a horse paste, a cattle injectable, or a human tablet for your dog.

Human meloxicam and equine products

Human meloxicam tablets are formulated for human body weights and human dosing intervals. Equine meloxicam paste is formulated for horses. Neither is appropriate for dogs. Using them risks a tenfold or greater dosing error, and the concentration on the package makes accurate canine dosing impossible without veterinary calculation.

How Meloxicam Compares With Alternatives

Other NSAIDs

Carprofen, firocoxib, deracoxib, ketoprofen, and robenacoxib are all canine NSAID options. The systematic review of NSAID adverse effects in dogs found high strength of evidence for carprofen, firocoxib, and meloxicam, moderate for deracoxib, ketoprofen, and robenacoxib, and low for etodolac [11]. Choice among these drugs depends on the individual dog, prior response, organ function, formulation preference, and cost.

Meloxicam has a pharmacokinetic profile distinct from ketoprofen. In the direct comparison study, meloxicam peaked much later and had a longer half-life than ketoprofen, which is why their dosing schedules differ [6].

Monoclonal antibody therapy

Bedinvetmab is a canine-specific monoclonal antibody against nerve growth factor, given as a monthly subcutaneous injection. In the head-to-head trial with daily oral meloxicam, both treatments reduced osteoarthritis pain scores significantly, and the between-group difference was not statistically significant [2]. A separate critical appraisal of bedinvetmab safety found conflicting evidence across four studies, with stronger evidence supporting its safety, and noted that in the two-month comparison with meloxicam, bedinvetmab had fewer associated adverse events [16].

This matters for owners of dogs that cannot tolerate NSAIDs. A non-NSAID injectable option exists, and it does not carry the same gastrointestinal and renal risk profile. It also does not replace the need for a diagnosis and a pain management plan.

Adjunctive therapies

Weight management, controlled exercise, physical rehabilitation, joint supplements, and environmental modification all reduce the load on arthritic joints. Meloxicam works best as one part of a multimodal plan, not as the only intervention.

Clinical Relevance, Limitations and Common Mistakes

The clinical relevance of meloxicam is straightforward. It is one of the best-studied NSAIDs in veterinary medicine, with high strength of evidence for safety and consistent efficacy data in osteoarthritis and perioperative pain [3][11][8][5]. For many dogs it is the first-line pharmaceutical answer to chronic joint pain.

The limitations are equally clear. Meloxicam does not treat the cause of pain. It can injure the stomach, kidney, and liver, particularly in dogs with pre-existing compromise. Its long half-life means dosing errors accumulate. And its efficacy varies by individual, which is why response should be assessed with a structured measure rather than a general impression.

Common mistakes owners make:

1. Using a human or equine product. The concentration and dosing interval are wrong for dogs.
2. Doubling up on NSAIDs. Adding aspirin or another NSAID to meloxicam raises the risk of ulceration.
3. Skipping baseline bloodwork. Without a baseline, a later kidney or liver change cannot be interpreted.
4. Giving the drug on an empty stomach. Food reduces direct gastric irritation.
5. Continuing the drug through vomiting or black stools. These are stop-and-call signs.
6. Giving a cat a dog's dose. Cats need a different, more conservative regimen.
7. Assuming a normal-looking dog is a safe dog. NSAID injury can be subclinical until it is advanced, which is why periodic lab work matters.

Individual dogs vary in how they handle meloxicam, and any decision to start, stop, or change the dose belongs with a veterinarian who knows the patient.

Frequently Asked Questions

Is meloxicam safe for long-term use in dogs?

Long-term use can be appropriate when the dog is monitored. Clinical trials have evaluated meloxicam over weeks in osteoarthritic dogs with acceptable tolerance, and safety depends on baseline organ function, correct dosing, and periodic rechecks [3][8].

Can I give my dog human meloxicam?

No. Human meloxicam products are formulated for human dosing and cannot be accurately dosed for a dog without veterinary calculation. Use only the veterinary product prescribed for your dog.

What should I do if my dog misses a dose?

Give the next scheduled dose at the normal time. Do not double up to make up for a missed dose, because meloxicam's long half-life means the drug accumulates.

Can meloxicam be given with steroids?

No. Combining an NSAID with a corticosteroid increases the risk of gastrointestinal ulceration and should be avoided unless a veterinarian has made a deliberate, closely monitored decision.

What are the first signs of a problem with meloxicam?

Vomiting, diarrhea, loss of appetite, and changes in stool color are the earliest and most common signs. Blood in the stool or black tarry stools require immediate veterinary contact [11][12].

How often does my dog need bloodwork while on meloxicam?

The interval is set by your veterinarian and depends on your dog's age, health status, and how long the drug is used. Baseline renal and hepatic panels plus a packed cell volume are the starting point, with periodic rechecks thereafter.

Is meloxicam the same as aspirin?

No. Aspirin irreversibly inhibits COX and affects platelets for days, while meloxicam is a reversible preferential COX-2 inhibitor with a different safety and dosing profile. They should not be combined.

Can meloxicam be used in cats?

Meloxicam is approved for cats, but the feline regimen is different and more conservative, often a single dose for acute indications. Cats are more sensitive to NSAID adverse effects than dogs, and a dog's dose should never be given to a cat [10].

Related Articles

• Enrofloxacin Baytril Dose: Fluoroquinolone Dose and Tendon Warning
• CBD Oil for Dogs: Dose Safety and Drug Interaction Warnings
• NPH Insulin Dogs Dose: Canine Diabetes Twice Daily Protocol
• Antimicrobial Stewardship in Canine Diarrhea: When Antibiotics Are Not the Answer
• Antimicrobial Stewardship in Canine Periodontal Disease: Antibiotic Use in Dentistry
• Corticosteroid Use in Canine Dermatology: A Practical Approach
• Metoclopramide for Dogs: Dose, Uses, Side Effects
• Enrofloxacin for Dogs: Uses, Dose, and Warnings
• Amantadine for Dogs: Uses, Doses, and Safety

Sources

1. [[Pharmacodynamic and pharmacokinetic aspects of the non-inflammatory non-steroidal agent meloxicam in dogs].](https://pubmed.ncbi.nlm.nih.gov/10220944/)
2. A randomised, parallel-group clinical trial comparing bedinvetmab to meloxicam for the management of canine osteoarthritis.
3. Clinical efficacy and tolerance of meloxicam in dogs with chronic osteoarthritis.
4. Meloxicam in Combination with Mitoxantrone or Vinblastine as First-Line Treatment for Non-Resectable Urothelial Cell Carcinoma in Dogs.
5. Evaluation of intravenous administration of meloxicam for perioperative pain management following stifle joint surgery in dogs.
6. A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs.
7. Preliminary bioequivalence of an oral integrating film formulation containing meloxicam with a suspension formulation in beagle dogs.
8. Multicenter randomized prospective clinical evaluation of meloxicam administered via transmucosal oral spray in client-owned dogs.
9. The effect of surgery (Ovariohysterectomy) on the plasma disposition of meloxicam following intravenous administration in dogs.
10. Long-term safety, efficacy and palatability of oral meloxicam at 0.01-0.03 mg/kg for treatment of osteoarthritic pain in cats.
11. Systematic review of nonsteroidal anti-inflammatory drug-induced adverse effects in dogs.
12. Use of Activated Carbon Hemoperfusion and Hemodialysis in the Treatment of a Meloxicam Overdose in a Dog.
13. Pharmacokinetic Profiles of Meloxicam and Sustained-release Buprenorphine in Prairie Dogs (Cynomys ludovicianus).
14. Comparative pharmacokinetics of a single oral dose of meloxicam in the California sea lion (Zalophus californianus) and Pacific harbor seal (Phoca vitulina richardii).
15. Comparison of the Inhibitory Effects of Flunixin Meglumine and Meloxicam on the Smooth Muscles Motility of the Gastrointestinal Tract of Cattle.
16. A critical appraisal of the safety of bedinvetmab (Beransa), a canine antinerve growth factor monoclonal antibody.